$DGX (Quest Diagnostics Inc.)

$DGX {{ '2016-04-14T20:31:09+0000' | timeago}} • Announcement

Diagnostic information services provider $DGX said it has included new capabilities in its chronic hepatitis C virus test services to help physicians identify resistance to HCV therapies. The services help physicians to determine the type, dose or duration of treatment with direct acting antiviral agents therapies that inhibit the NS5A protein.

$DGX {{ '2017-08-18T14:15:24+0000' | timeago}} • Announcement

$DGX declared a quarterly cash dividend of $0.45 per share, payable on Oct 18, 2017 to shareholders as on Oct 3, 2017.

$DGX {{ '2017-07-18T13:54:10+0000' | timeago}} • Announcement

Medical diagnostics firm $DGX has completed the acquisition of laboratory businesses Med Fusion and Clear Point. They form the basis for Quest’s first national center of excellence in precision diagnostics for oncology. The company is now a preferred provider to several organizations that are formerly owners of one or both of the acquired entities.

$DGX {{ '2017-06-27T17:25:22+0000' | timeago}} • Announcement

$DGX signed a nonbinding letter of intent to buy the outreach laboratory services business of Cape Cod Healthcare (CCHC) for undisclosed terms. Upon approval by the Massachusetts Health Policy Commission, the organizations expect to complete the transaction by Jan. 1, 2018.

$DGX {{ '2017-06-12T20:40:28+0000' | timeago}} • Announcement

$DGX to acquire two laboratory businesses in Lewisville, Texas, aiming to establish a center of excellence providing diagnostic services to aid the detection and management of cancer for oncologists and patients. Upon transaction completion, $DGX will be a preferred provider of advanced oncology diagnostics for US Oncology Network.

$DGX {{ '2017-05-16T16:20:25+0000' | timeago}} • Announcement

$DGX declared a quarterly cash dividend of $0.45 per share, payable on July 24, 2017 to shareholders of record of Quest Diagnostics common stock on July 10, 2017.

$DGX {{ '2017-04-20T14:12:14+0000' | timeago}} • Webcast

$DGX said that its partnership with their computing partner $IBM is progressing well in oncology business. The company said that it uses IBM Watson Health in the cancer treatment. $DGX believes IBM's sales force and their presence with integrated delivery systems will help the company.

$DGX {{ '2017-04-20T13:45:15+0000' | timeago}} • Webcast

$DGX said that its relationship with United Healthcare, which was announced in 4Q16, is progressing well. The company is working with United in wellness and professional laboratory services businesses. $DGX believes that its relationship with United will get stronger over time.

$DGX {{ '2017-04-20T12:38:29+0000' | timeago}} • Announcement

$DGX raised its outlook for EPS in FY17 to $4.73-4.88 from the previous guidance of $4.65-4.80. Adjusted EPS was also raised to $5.45-5.60. The upgrades reflect higher-than-expected excess tax benefit related to stock-based compensation in 1Q17.

$DGX {{ '2017-04-20T12:32:08+0000' | timeago}} • Announcement

Clinical laboratory services company $DGX posted a 2% rise in net revenue in 1Q17 to $1.89Bil. Net income attributable to $DGX was $164MM, or $1.16 per share, compared to $103MM, or $0.61 per share in the year-ago quarter. Adjusted for one-off items, EPS was $1.33.

$DGX {{ '2017-02-21T15:32:26+0000' | timeago}} • Announcement

$DGX's BoD declared a quarterly cash dividend of $0.45 per share, payable on April 19, 2017 to shareholders of record of common stock on April 5, 2017.

$DGX {{ '2017-02-16T14:08:46+0000' | timeago}} • Announcement

In an undisclosed deal, $DGX acquired outreach lab services of PeaceHealth Laboratories, a not-for-profit health system. The company will manage PeaceHealth's 11 labs, which will be owned by PeaceHealth. These labs are located within PeaceHealth's medical centers in three states. This transaction is expected to close in 2Q17.

$VCYT {{ '2017-02-09T18:03:58+0000' | timeago}} • Announcement

$VCYT said it will extend access to its Afirma Gene Expression Classifier (GEC) through an agreement with $DGX, a provider of diagnostic information services. The agreement is intended to meet growing physician demand for innovative genomic testing services to improve thyroid cancer diagnosis. $DFX is expected to begin offering the test in 2Q17.

$DGX {{ '2017-01-26T12:25:32+0000' | timeago}} • Announcement

$DGX said it expects 2017 earnings of $4.65-$4.80 per share, and adjusted diluted EPS excluding amortization in the range of $5.37-5.52. Revenue on a reported basis for 2017 is expected in the range of $7.64-7.72Bil, while cash provided by operations is expected to be approx. $1.1Bil. CapEx for 2017 is expected in the range of $250-300MM.

$DGX {{ '2017-01-26T12:21:41+0000' | timeago}} • Announcement

Healthcare company $DGX reported 4Q16 net income of $155MM, or $1.09 per share, a decline of 17.55% from $188MM, or $1.29 per share a year ago. Revenue for the quarter rose 0.64% to $1.86Bil on a reported basis, while it was up 1.9% on an equivalent basis.

$DGX {{ '2016-12-15T22:02:54+0000' | timeago}} • Announcement

$DGX said its BoD elected Stephen H. Rusckowski, the company's President and Chief Executive Officer, to serve in the additional position of Chairman of the BoD.

$DGX {{ '2016-11-21T12:37:52+0000' | timeago}} • Announcement

$DGX said it launched QuestDirect, a new Patient-Initiated Testing service. This will empower consumers who live in Colorado and Missouri to manage their health by ordering certain lab tests without a physician's order. The pilot program will be available beginning today.

$DGX {{ '2016-11-11T13:21:19+0000' | timeago}} • Announcement

$DGX reaffirmed its 2016 revenue of about $7.51Bil, an increase of 2.5% over 2015 on equivalent basis. The company projects adjusted EPS of $5.07-5.12, cash provided by operations of about $1Bil and capital expenditures of about $250MM.

$DGX {{ '2016-11-11T13:19:34+0000' | timeago}} • Announcement

$DGX's BoD increased its quarterly dividend from $0.40 to $0.45 per share. The dividend is payable on Jan. 25, 2017 to shareholders of record on Jan. 10, 2017. Additionally, the company has invested about $1Bil in 10 acquisitions since 2012.

$DGX {{ '2016-11-11T13:17:57+0000' | timeago}} • Announcement

$DGX lifted revenue growth outlook for period 2017-2020 to be 3-5%. Earnings for same period are expected to grow faster than revenue in mid-to-high single digit range. In addition, the company raised dividend by 12.5% to annual rate of $1.80 per share.

$DGX {{ '2016-10-20T20:07:04+0000' | timeago}} • Webcast

$DGX stated that its partnership with Squared is progressing. Both the companies will get benefited by integrating their laboratory clinical trial businesses. $DGX will get 40% of the equity earnings since it owns 40% of the joint venture. The company added that it will take some time to get the integration completed.

Recent Transcripts

PDCO (Patterson Companies, Inc.)
Thursday, August 24 2017 - 2:00pm
MYGN (Myriad Genetics, Inc.)
Tuesday, August 8 2017 - 8:30pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
WCG (WellCare Health Plans, Inc.)
Friday, August 4 2017 - 1:00pm
CI (Cigna Corp.)
Friday, August 4 2017 - 12:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
MOH (Molina Healthcare, Inc.)
Wednesday, August 2 2017 - 9:00pm
BMRN (BioMarin Pharmaceutical Inc.)
Wednesday, August 2 2017 - 8:30pm
HOLX (Hologic Inc.)
Wednesday, August 2 2017 - 8:30pm
HUM (Humana Inc.)
Wednesday, August 2 2017 - 1:00pm
OMI (Owens & Minor Inc.)
Wednesday, August 2 2017 - 12:00pm
INCY (Incyte Corporation)
Tuesday, August 1 2017 - 2:00pm
GNMK (GenMark Diagnostics, Inc.)
Tuesday, August 1 2017 - 12:30pm
ROP (Roper Technologies, Inc.)
Monday, July 31 2017 - 12:30pm
QGEN (Qiagen NV)
Friday, July 28 2017 - 1:00pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
ADP (Automatic Data Processing Inc)
Thursday, July 27 2017 - 12:30pm
Thursday, July 27 2017 - 12:00pm

AlphaGraphics you may like